VJHemOnc is committed to improving our service to you

MPN Advances Day 2019 | DESTINY update: achieving TFR by de-escalating TKI therapy in CML

VJHemOnc is committed to improving our service to you

Mhairi Copland

Mhairi Copland, MB ChB, PhD, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the DESTINY trial (NCT01804985). This trial aimed to examine the effects of gradual treatment withdrawal and whether TFR is feasible for chronic myeloid leukemia (CML) patients with less deep but stable remission. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter